Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Silvestrol SCHEMBL29391620 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19678561 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| 2'-Episilvestrol SCHEMBL29384144 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19683897 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL24180257 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19666161 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL24426807 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL29959484 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL5807124 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19508495 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20250255894-A1 | INHIBITORS OF EIF4A | Aceae Nutra Limited (GB) | 2025-08-14 | — | — | US | claimed |
| WO-2025137577-A1 | SHORT VIRAL RNAS (SVRNAS) WITH THERAGNOSTIC POTENTIAL IN INFECTION WITH SARS-COV-2 AND RELATED VIRUSES | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4554571-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2025093619-A1 | BOOSTING CAP-INDEPENDENT TRANSLATION | CIRCIO AB (SE) | 2025-05-08 | — | — | WO | claimed |
| WO-2025071306-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING LYMPHOMA COMPRISING BCL-2 INHIBITOR, SELECTIVE NUCLEAR EXPORT PROTEIN INHIBITOR, AND ELF4A INHIBITOR | 연세대학교 산학협력단 | 2025-04-03 | — | — | WO | claimed |
| EP-4489763-A1 | INHIBITORS OF EIF4A | Aceae Nutra Limited (GB) | 2025-01-15 | — | — | EP | claimed |
| US-20240393340-A1 | PROGNOSIS AND PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-28 | — | — | US | claimed |
| WO-2024107624-A1 | METHODS OF OVERCOMING RESISTANCE TO CHECKPOINT INHIBITOR THERAPIES | SHATTUCK LABS, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024016000-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-18 | — | — | WO | claimed |
| US-20150224132-A1 | COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-08-13 | — | — | US | claimed |
| WO-2015120350-A2 | COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASE | EFFECTOR THERAPEUTICS, INC. (US) | 2015-08-13 | — | — | WO | claimed |
| US-20150219624-A1 | METHODS FOR IDENTIFYING ANTI-CANCER COMPOUNDS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2015-08-06 | — | — | US | claimed |
| WO-2015085221-A2 | METHODS FOR IDENTIFYING ANTI-CANCER COMPOUNDS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2015-06-11 | — | — | WO | claimed |
| US-20150087598-A1 | TREATING MUC1-EXPRESSING CANCERS WITH HELICASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-03-26 | — | — | US | claimed |
| WO-2014184211-A1 | PROGNOSIS AND PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF | INSTITUT GUSTAVE ROUSSY (FR) | 2014-11-20 | — | — | WO | claimed |
| US-20140255432-A1 | SILVESTROL, SILVESTROL ANALOGS AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2014-09-11 | — | — | US | claimed |
| WO-2013170257-A1 | TREATING MUC1-EXPRESSING CANCERS WITH HELICASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-11-14 | — | — | WO | claimed |
| WO-2013016658-A1 | SILVESTROL, SILVESTROL ANALOGS AND USES THEREOF | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-01-31 | — | — | WO | claimed |
| US-20090186839-A1 | Model for studying the role of genes in chemoresistance | COLD SPRING HARBOR LABORATORY (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087598-A1 | TREATING MUC1-EXPRESSING CANCERS WITH HELICASE INHIBITORS | MUC1, DDX21, DDX39B | EIF4A1 30/4885CYP3A4 4608/4885HIF1A 1690/4885 |
| US-20140255432-A1 | SILVESTROL, SILVESTROL ANALOGS AND USES THEREOF | CD4, HAVCR2, IFNG | EIF4A1 2206/4885CYP3A4 2559/4885HIF1A 1552/4885 |
| US-20250255894-A1 | INHIBITORS OF EIF4A | EIF4A1, EIF4EBP1, EIF4E | EIF4A1 1/4885CYP3A4 4495/4885HIF1A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.